Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9THJ

Crystal structure of H5N1 influenza polymerase PB2 domain in complex with compound 3

This is a non-PDB format compatible entry.
Summary for 9THJ
Entry DOI10.2210/pdb9thj/pdb
DescriptorPolymerase basic protein 2, (1~{R},2~{S},4~{R},5~{S},6~{S},7~{S})-7-[[5-fluoranyl-2-(5-fluoranyl-1~{H}-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl]amino]tricyclo[3.2.2.0^{2,4}]nonane-6-carboxylic acid, SULFATE ION, ... (4 entities in total)
Functional Keywordstransferase, influenza polymerase, cap-binding inhibitors
Biological sourceInfluenza A virus (A/duck/Shantou/4610/2003(H5N1))
More
Total number of polymer chains1
Total formula weight18756.65
Authors
Kuglstatter, A.,Ehler, A. (deposition date: 2025-12-03, release date: 2026-01-28)
Primary citationWu, J.,Liu, Y.,Li, D.,Wang, L.,Neidhart, W.,Chen, B.,Hochstrasser, R.,Kuglstatter, A.,Gasser, R.,Qiu, H.,Shi, T.,Chao, S.K.,Gao, J.,Shen, H.C.,Tan, X.
Discovery of Potent and Efficacious Influenza PB2 Inhibitors.
Acs Med.Chem.Lett., 17:249-256, 2026
Cited by
PubMed Abstract: In pursuit of potent, efficacious influenza inhibitors with novel mechanisms, we replaced the 7-azaindole core of the PB2 inhibitor pimodivir (VX-787/JNJ872) with a 7-fluoro-substituted indazole to mitigate CYP3A- and aldehyde oxidase-mediated metabolism by lowering lipophilicity and blocking the metabolic soft spot. We further introduced a cyclopropyl-fused ring onto the bridged bicyclo[2.2.2]-octane to retain potency while reducing glucuronidation. This design converged in compound , where the indazole scaffold and fused cyclopropyl ring acted synergistically to improve the potency and pharmacokinetic properties. In a lethal influenza mouse challenge model, compound achieved approximately a 7-fold reduction in the effective dose compared with pimodivir. It also showed significantly improved activity against selected influenza A strains versus pimodivir, highlighting its potential as a differentiated PB2 inhibitor.
PubMed: 41531980
DOI: 10.1021/acsmedchemlett.5c00674
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (0.91 Å)
Structure validation

250359

PDB entries from 2026-03-11

PDB statisticsPDBj update infoContact PDBjnumon